Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
California dermatology
mi
from
Encinitas, CA
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
California dermatology
mi
from
Encinitas, CA
Click here to add this to my saved trials
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated:  12/31/1969
USC Department of Dermatology
mi
from
Los Angeles, CA
Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)
A Randomised, Double-blind, Placebo-controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Tralokinumab Monotherapy in Subjects With Moderate to Severe Atopic Dermatitis Who Are Candidates for Systemic Therapy
Status: Enrolling
Updated: 12/31/1969
USC Department of Dermatology
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
Fremont, CA
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
Fremont, CA
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
Los Angeles, CA
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
San Diego, CA
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
San Diego, CA
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
San Luis Obispo, CA
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
San Luis Obispo, CA
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
Louisville, KY
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
Louisville, KY
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
Berlin, NJ
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
Berlin, NJ
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
Portland, OR
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
Portland, OR
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
Hershey, PA
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
Hershey, PA
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
Johnston, RI
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
Johnston, RI
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigational Site
mi
from
Dallas, TX
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
Houston, TX
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
Houston, TX
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
San Antonio, TX
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Dermavant Investigator Site
mi
from
Norfolk, VA
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Dermavant Investigator Site
mi
from
Norfolk, VA
Click here to add this to my saved trials
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated:  12/31/1969
Research Site
mi
from
Surrey,
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Study of RVT-501 in Adult and Adolescent Subjects With Atopic Dermatitis
Status: Enrolling
Updated: 12/31/1969
Research Site
mi
from
Surrey,
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site (8568)
mi
from
New York, NY
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site (8568)
mi
from
New York, NY
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Waco, TX
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Waco, TX
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Benowa,
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Benowa,
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site (# 8456)
mi
from
Beverly Hills, CA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site (# 8456)
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site (8571)
mi
from
Darien, IL
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site (8571)
mi
from
Darien, IL
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site (# 8532)
mi
from
Overland Park, KA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site (# 8532)
mi
from
Overland Park, KA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site
mi
from
Birmingham, AL
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Fort Smith, AR
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Fort Smith, AR
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site
mi
from
Fountain Valley, CA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site
mi
from
Fountain Valley, CA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site (# 8224)
mi
from
Fremont, CA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site (# 8224)
mi
from
Fremont, CA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site
mi
from
Rolling Hills Estates, CA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site
mi
from
Rolling Hills Estates, CA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Santa Ana, CA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Santa Ana, CA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Santa Monica, CA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Santa Monica, CA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Miami, FL
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Miami, FL
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site (# 8523)
mi
from
Tampa, FL
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site (# 8523)
mi
from
Tampa, FL
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site
mi
from
Columbus, GA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site
mi
from
Columbus, GA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site
mi
from
Sandy Springs, GA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site
mi
from
Sandy Springs, GA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site (8580)
mi
from
New Orleans, LA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site (8580)
mi
from
New Orleans, LA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site
mi
from
Forest Hills, NY
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site
mi
from
Forest Hills, NY
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Chapel Hill, NC
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Johnston, RI
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Johnston, RI
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Dallas, TX
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
San Antonio, TX
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational site
mi
from
Richmond, VA
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational site
mi
from
Richmond, VA
Click here to add this to my saved trials
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated:  12/31/1969
Galderma Investigational Site
mi
from
Farmington Hills, MI
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
Randomized, Double-blind, Multi-center, Parallel-group, Placebo-controlled Dose-ranging Study to Assess the Efficacy and Safety of Nemolizumab in Moderate-to-severe Atopic Dermatitis Subjects With Severe Pruritus Receiving TCS
Status: Enrolling
Updated: 12/31/1969
Galderma Investigational Site
mi
from
Farmington Hills, MI
Click here to add this to my saved trials
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Southern California Permanente Medical Group
mi
from
Los Angeles, CA
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Southern California Permanente Medical Group
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Dermatology Specialists, Inc.
mi
from
Oceanside, CA
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Dermatology Specialists, Inc.
mi
from
Oceanside, CA
Click here to add this to my saved trials
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Medderm Associates
mi
from
San Diego, CA
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Medderm Associates
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
San Luis Dermatology & Laser Clinic, Inc.
mi
from
San Luis Obispo, CA
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
San Luis Dermatology & Laser Clinic, Inc.
mi
from
San Luis Obispo, CA
Click here to add this to my saved trials
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Southern California Dermatology, Inc.
mi
from
Santa Ana, CA
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Southern California Dermatology, Inc.
mi
from
Santa Ana, CA
Click here to add this to my saved trials
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of Connecticut
mi
from
Danbury, CT
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of Connecticut
mi
from
Danbury, CT
Click here to add this to my saved trials
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Florida Academic Dermatology Centers
mi
from
Coral Gables, FL
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Florida Academic Dermatology Centers
mi
from
Coral Gables, FL
Click here to add this to my saved trials
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Renstar Medical Research
mi
from
Ocala, FL
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Renstar Medical Research
mi
from
Ocala, FL
Click here to add this to my saved trials
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  12/31/1969
Park Avenue Dermatology
mi
from
Orange Park, FL
A Study to Evaluate the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
A Phase 3, Multicenter, Randomized, Double-blind Study Evaluating the Comparative Efficacy of CNTO 1959 (Guselkumab) and Secukinumab for the Treatment of Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 12/31/1969
Park Avenue Dermatology
mi
from
Orange Park, FL
Click here to add this to my saved trials